These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 38504051)
1. Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making. Chatterjee S; Mair M; Shaha AR; Paleri V; Sawhney S; Mishra A; Bhandarkar S; D'Cruz AK Endocrine; 2024 Aug; 85(2):509-519. PubMed ID: 38504051 [TBL] [Abstract][Full Text] [Related]
2. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. Ibrahimpasic T; Ghossein R; Shah JP; Ganly I Thyroid; 2019 Mar; 29(3):311-321. PubMed ID: 30747050 [TBL] [Abstract][Full Text] [Related]
9. FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature. Saglietti C; Onenerk AM; Faquin WC; Sykiotis GP; Ziadi S; Bongiovanni M Cytopathology; 2017 Dec; 28(6):467-474. PubMed ID: 29094425 [TBL] [Abstract][Full Text] [Related]
10. High-Grade Non-Anaplastic Thyroid Carcinomas of Follicular Cell Origin: A Review of Poorly Differentiated and High-Grade Differentiated Carcinomas. Cracolici V; Cipriani NA Endocr Pathol; 2023 Mar; 34(1):34-47. PubMed ID: 36692728 [TBL] [Abstract][Full Text] [Related]
11. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome. Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765 [TBL] [Abstract][Full Text] [Related]
12. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma. Xu B; Ghossein R Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303 [TBL] [Abstract][Full Text] [Related]
13. Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Luo Y; Jiang H; Xu W; Wang X; Ma B; Liao T; Wang Y Front Oncol; 2020; 10():549882. PubMed ID: 33117686 [No Abstract] [Full Text] [Related]
14. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma. Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630 [No Abstract] [Full Text] [Related]
15. The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review. Violetis O; Konstantakou P; Spyroglou A; Xydakis A; Kekis PB; Tseleni S; Kolomodi D; Konstadoulakis M; Mastorakos G; Theochari M; Aller J; Alexandraki KI J Pers Med; 2024 Jun; 14(6):. PubMed ID: 38929875 [TBL] [Abstract][Full Text] [Related]
16. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Chernock RD; Rivera B; Borrelli N; Hill DA; Fahiminiya S; Shah T; Chong AS; Aqil B; Mehrad M; Giordano TJ; Sheridan R; Rutter MM; Dehner LP; Foulkes WD; Nikiforov YE Mod Pathol; 2020 Jul; 33(7):1264-1274. PubMed ID: 31937902 [TBL] [Abstract][Full Text] [Related]
17. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400 [TBL] [Abstract][Full Text] [Related]
18. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243 [TBL] [Abstract][Full Text] [Related]